Company intelligence / Profile preview

Biodol Therapeutics

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Biodol Therapeutics is a French biotechnology company dedicated to developing first-in-class compounds for the treatment of chronic pain. The company focuses on a novel mechanism of action by targeting the Fms-like tyrosine kinase 3 (FLT3) receptor, which has been identified as a key player in the transition from acute to chronic neuropathic pain. Their lead program involves small molecule inhibitors designed to provide long-lasting relief without the side effects associated with current analgesics like opioids. Biodol's research is based on discoveries from the Institute for Functional Genomics (IGF) and the Montpellier Institute for Neurosciences (INM).

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

3 assets

BDT272

2 more assets in the full pipeline.

Partnerships

InsermCNRSUniversity of Montpellier

Beyond the preview

Go deeper on Biodol Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biodol Therapeutics.